Macquarie analyst Tao Qiu initiated coverage of Astrana Health (ASTH) with a Neutral rating and $41 price target Astrana has built a profitable value-based care model, leveraging a home-grown technology platform and a combination of provider partnerships and company-operated care clinics, the analyst tells investors. However, expansion into new markets and large acquisitions create margin headwinds amid industry-wide challenges, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health to Share Financial Insights at Conferences
- Astrana Health price target raised to $86 from $67 at Baird
- Astrana Health Grants Equity Awards to Key Executives
- Astrana Health Acquires Prospect Health for $745 Million
- Medical Properties Trust prospect to sell managed care unit to Astrana for $745M